Unknown

Dataset Information

0

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.


ABSTRACT: BACKGROUND:This systematic review and meta-analysis included double-blind, randomized, placebo-controlled trials of brexpiprazole adjunctive treatment (0.5-3 mg/d) for major depressive disorder where antidepressant treatment had failed. METHODS:The outcomes were the response rate (primary), remission rate (secondary), Montgomery Åsberg Depression Rating Scale score (secondary), Sheehan Disability Scale scores (secondary), Clinical Global Impression-Improvement/Severity scores, discontinuation rate, and individual adverse events. A subgroup meta-analysis of the data at week 6 compared outcomes by dose >2 mg/d or ?2 mg/d (2 mg/d is the recommended dose). RESULTS:We identified 9 studies (n?=?3391). Compared with placebo, brexpiprazole (any dose) was superior for response rate (risk ratio [RR]?=?0.93, 95% confidence interval [95% CI]?=?0.89-0.97, number needed to treat?=?17), remission rate (RR?=?0.95, 95% CI?=?0.93-0.98, number needed to treat?=?25), Montgomery Åsberg Depression Rating Scale score (standardized mean difference =?-0.20, 95% CI?=?-0.29, -0.11), Sheehan Disability Scale score (standardized mean difference?=?-0.12, 95% CI?=?-0.21, -0.04), and Clinical Global Impression-Improvement/Severity scores but was associated with a higher discontinuation rate, akathisia, insomnia, restlessness, somnolence, and weight increase. Doses >2 mg/d had a significantly higher RR for response rate than ?2 mg/d (0.96 vs 0.89); moreover, compared with placebo, doses >2 mg/d were associated with higher incidences of akathisia (RR?=?4.58) and somnolence (RR?=?7.56) as well as were marginally associated with a higher incidence of weight increase (RR?=?3.14, P?=?.06). Compared with placebo, doses ?2 mg/d were associated with higher incidences of akathisia (RR?=?2.28) and weight increase (RR?=?4.50). CONCLUSIONS:Brexpiprazole adjunctive treatment is effective for major depressive disorder when antidepressant treatment fails. At 6 weeks, doses ?2 mg/d presented a better risk/benefit balance than >2 mg/d.

SUBMITTER: Kishi T 

PROVIDER: S-EPMC6872963 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.

Kishi Taro T   Sakuma Kenji K   Nomura Ikuo I   Matsuda Yuki Y   Mishima Kazuo K   Iwata Nakao N  

The international journal of neuropsychopharmacology 20191101 11


<h4>Background</h4>This systematic review and meta-analysis included double-blind, randomized, placebo-controlled trials of brexpiprazole adjunctive treatment (0.5-3 mg/d) for major depressive disorder where antidepressant treatment had failed.<h4>Methods</h4>The outcomes were the response rate (primary), remission rate (secondary), Montgomery Åsberg Depression Rating Scale score (secondary), Sheehan Disability Scale scores (secondary), Clinical Global Impression-Improvement/Severity scores, dis  ...[more]

Similar Datasets

| S-EPMC5064333 | biostudies-literature
| S-EPMC5412581 | biostudies-literature
| S-EPMC8090770 | biostudies-literature
| S-EPMC6175103 | biostudies-literature
| S-EPMC6305164 | biostudies-literature
| S-EPMC6403084 | biostudies-literature
| S-EPMC10428010 | biostudies-literature
| S-EPMC6007711 | biostudies-other
| S-EPMC5171769 | biostudies-literature
2023-03-07 | PXD034030 | Pride